Gout Dose Response Study
5. Februar 2014 aktualisiert von: Ardea Biosciences, Inc.
Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients With Gout
To compare the proportion of subjects whose serum urate (sUA) level is < 6.0 mg/dL after 28 days of dosing by treatment group.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
123
Phase
- Phase 2
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
-
Pleven, Bulgarien, 5800
-
Plovdiv, Bulgarien, 4002
-
Plovidv, Bulgarien, 4002
-
Sofia, Bulgarien, 1233
-
Sofia, Bulgarien, 1709
-
Varna, Bulgarien, 9010
-
-
-
-
-
Goch, Deutschland, 47574
-
Hamburg, Deutschland, 22143
-
Nuremberg, Deutschland, 90402
-
-
-
-
-
Tbilisi, Georgia, 0186
-
Tbilisi, Georgia, 0102
-
-
-
-
British Columbia
-
Coquitlam, British Columbia, Kanada, V3K 3P4
-
Kelowna, British Columbia, Kanada, V1Y8E7
-
-
Ontario
-
Thornhill, Ontario, Kanada, L4J6W6
-
Toronto, Ontario, Kanada, M9W 4L6
-
-
Quebec
-
Mirabel, Quebec, Kanada, J7J 2K8
-
-
-
-
-
Elblag, Polen, 82-300
-
Lodz, Polen, 90-153
-
Lublin, Polen, 20-607
-
Poznan, Polen, 61-289
-
Radom, Polen, 26-610
-
Wroclaw, Polen, 53-025
-
-
-
-
-
Bruntal, Tschechische Republik, 792 01
-
Prague, Tschechische Republik, 140 00
-
Prague, Tschechische Republik, 148 00
-
-
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90017
-
-
Florida
-
DeLand, Florida, Vereinigte Staaten, 32720
-
-
North Carolina
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27103
-
-
Tennessee
-
Jackson, Tennessee, Vereinigte Staaten, 38305
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Male or post-menopausal or surgically sterile female.
- 18 - 75 years of age.
- Hyperuricemic (i.e., screening sUA ≥8 mg/dL).
- Meets criteria for the diagnosis of gout as per the American Rheumatism Association (ARA) Criteria for the Classification of Acute Arthritis of Primary Gout.
- Willing and able to give informed consent and adhere to visit/protocol schedules (informed consent must be given before the first study procedure is performed).
- Subjects entering the optional Extension Period must have successfully completed the Double-Blind Treatment Period and Follow-up Period within approximately 4 months and must not have experienced any serious adverse events considered possibly related to study drug.
Exclusion Criteria:
- Classified as an overproducer of urine urate (Cur > 6.0 ml/min/1.73 m2 24- hour urine).
- Consumes more than 14 drinks of alcohol per week (e.g., 1 drink = 5 oz [150 ml] of wine, 12 oz [360 ml] of beer, or 1.5 oz [45 ml] of hard liquor).
- History or suspicion of drug abuse.
- Documented history of or suspicion of kidney stones.
- History of rheumatoid arthritis or other autoimmune disease.
- Confirmed (positive serology to HIV1 and HIV 2) or suspected HIV infection.
- Positive serology to HCV antibodies (Abs), and/or hepatitis B surface antigen (HBsAg).
- History of malignancy, except treated non-melanomatous skin cancer or cervical dysplasia.
- History of cardiac abnormalities, including abnormal and clinically relevant ECG changes such as bradycardia (sinus rate <45 bpm), complete left bundle branch block (LBBB), second or third degree heart block, intraventricular conduction delay with QRS duration >120 msec, symptomatic or asymptomatic arrhythmias with the exception of sinus arrhythmia, evidence of ventricular pre-excitation, frequent palpitations or syncopal episodes, heart failure, hypokalemia, family history of Long QT Syndrome, and/or family history of sudden death in an otherwise healthy individual between the ages of 1 and 30 years.
- Any condition predisposing them to QT prolongation including pathological Q-wave (defined as Q-wave >40 msec or depth > 0.4-0.5 mV).
- Any use of a concomitant medication that prolong the QT/QTc interval within the 14 days prior to Baseline (Day 0)
- QT interval corrected for heart rate according to Fridericia (QTcF) > 450 msec at Screening or pre-dose at Baseline (Day 0)
- Uncontrolled hypertension (above 150/95)
- Inadequate renal function
- Hemoglobin < 10 g/dL (males) or < 9 g/dL (females)
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x upper limit of normal (ULN)
- Gamma glutamyl transferase (GGT) > 3 x ULN
- Active peptic ulcer disease requiring treatment
- History of xanthinuria, active liver disease, or hepatic dysfunction.
- Requires therapy with any other urate-lowering medication, other than the study medication.
- Requires long-term use of salicylates; diuretics; azathioprine; mercaptopurine; theophylline; intravenous colchicine; cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole; or trimethoprim
- Taking medications known as enzyme inducers
- Receiving a strong or moderate inhibitor of CYP3A4 or a P-gp inhibitor within 1 month prior to study drug dosing
- Gout flare at screening that is resolved for less than one week prior to the first treatment with study medication (exclusive of chronic synovitis/ arthritis)
- Female of childbearing potential
- Received an investigational medication within 4 weeks prior to study medication administration
- Previously participated in a clinical study involving RDEA806 or RDEA594.
- Known hypersensitivity or allergy to RDEA594 or colchicine or any components in their formulations.
- Body mass index (BMI) >40 kg/m2.
- Taking greater than 1000 mg/day of Vitamin C.
- Any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.
- Inadequate renal function after completing the Double-Blind Treatment period prior to entering Extension Period.
- Requiring treatment with prohibited medications noted in exclusion criteria numbers 20-23 after completing the Double-Blind Treatment Period prior to entering the Extension Period.
- Clinically relevant medical event as determined by the investigator in consultation with medical monitor prior to entering the Extension Period.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: RDEA594 200 mg qd for 28 days
|
Uricosuric agent for the treatment of gout
|
|
Experimental: RDEA594 200 mg, 400 mg
RDEA594 200 mg qd for 7 days followed by 400 mg qd for 21 days
|
Uricosuric agent for the treatment of gout
|
|
Experimental: RDEA594 200 mg, 400 mg and 600 mg
RDEA594 200 mg qd for 7 days followed by 400 mg qd for 7 days followed by 600 mg qd for 14 days
|
Uricosuric agent for the treatment of gout
|
|
Placebo-Komparator: Matching placebo
RDEA594 matching placebo qd for 28 days
|
Passendes Placebo
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
To compare the proportion of subjects whose serum urate (sUA) level is < 6.0 mg/dL after 28 days of dosing by treatment group.
Zeitfenster: 28 Days
|
28 Days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
To evaluate the proportion of subjects whose sUA levels are <6.0 mg/dL, <5.0 mg/dL and <4.0 mg/dL at each weekly study visit during the Double-Blind Period.
Zeitfenster: 28 Days
|
28 Days
|
|
To evaluate the absolute and percent reduction from baseline in sUA levels at each weekly study visit.
Zeitfenster: 28 Days and through extension
|
28 Days and through extension
|
|
To evaluate the percentage change in 24-hour urine urate level (excretion) from baseline to Day 28.
Zeitfenster: 28 Days and through extension
|
28 Days and through extension
|
|
To evaluate the incidence of gout flares.
Zeitfenster: 28 Days and through extension
|
28 Days and through extension
|
|
To evaluate the safety and tolerability of RDEA594 in subjects with gout.
Zeitfenster: 28 Days and through extension
|
28 Days and through extension
|
|
To evaluate the proportion of subjects whose sUA level decreases to or is maintained at <6.0 mg/dL in the Open-Label Extension Period.
Zeitfenster: 18 Months
|
18 Months
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Studienleiter: Vijay Hingorani, MD, PhD, MBA, Ardea Biosciences, Inc.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Juli 2009
Primärer Abschluss (Tatsächlich)
1. März 2010
Studienabschluss (Tatsächlich)
1. September 2011
Studienanmeldedaten
Zuerst eingereicht
7. August 2009
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
7. August 2009
Zuerst gepostet (Schätzen)
10. August 2009
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
7. März 2014
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
5. Februar 2014
Zuletzt verifiziert
1. Februar 2014
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- RDEA594-202
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .